Login to Your Account



Eisai's Eritoran Setback Puts Sepsis Drug on Critical List

By Marie Powers


Wednesday, January 26, 2011
The failure of Eisai Inc.'s eritoran (E5564) to meet its primary Phase III endpoint of reducing 28-day all-cause mortality in patients with severe sepsis may have relegated yet another candidate to the graveyard of failures for this indication.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription